Home › Trials › NCT06506084

Observing the effects of ropeginterferon alfa-2b in patients with Polycythemia Vera

Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)

Observational FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS · NCT06506084

This study is testing how well the drug ropeginterferon alfa-2b works and is tolerated by people with Polycythemia Vera who need treatment.

Quick facts

Study typeObservational
Enrollment319 (estimated)
Ages18 Years to 100 Years
SexAll
SponsorFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS Academic / other
Locations37 sites (Bergamo, Lombardia and 36 other locations)
Trial IDNCT06506084 on ClinicalTrials.gov

What this trial studies

This observational study aims to evaluate the use of ropeginterferon alfa-2b in patients diagnosed with Polycythemia Vera (PV). It will assess how well the drug can be prescribed and tolerated in real-world clinical settings, focusing on the risk-benefit profile of the treatment. The study will include patients who require cytoreductive treatment and will follow them over time to gather data on the drug's effectiveness and safety. The findings will help inform clinical practice for managing PV.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with Polycythemia Vera who require cytoreductive treatment.

Not a fit: Patients with contraindications for ropeginterferon alfa-2b will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could improve treatment strategies and quality of life for patients with Polycythemia Vera.

How similar studies have performed: Other studies have shown promising results with similar treatments for Polycythemia Vera, indicating potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patients diagnosed with Polycythemia Vera by WHO 2016
* Patient aged ≥ 18 years old
* Patients in need of cytoreductive treatments with ropeginterferon alfa-2b in first or later lines according to the reimbursability criteria defined by the Italian National Health System
* Patients who have signed the written informed consent for study participation.

Exclusion Criteria:

• Any contraindication for ropeginterferon alfa-2b according to the SmPC

Where this trial is running

Bergamo, Lombardia and 36 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Polycythemia Vera
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.